Atherosclerosis, Год журнала: 2024, Номер unknown, С. 118583 - 118583
Опубликована: Сен. 1, 2024
Язык: Английский
Deleted Journal, Год журнала: 2023, Номер 1(4)
Опубликована: Окт. 1, 2023
Abstract Liquid biopsy has emerged as a promising avenue for non‐invasive and rapid retrieval of pathological information from patient body fluids. Over the years, liquid garnered significant attention clinically treating cancer by selecting appropriate biomarkers such circulating tumor cells (CTCs) extracellular vesicles (EVs). Further integration advanced technologies facilitated efficient capture biopsy, revolutionizing clinical decision‐making in multiple processes stages patients. Underscoring intersection different disciplines, this review provides holistic summary recent breakthroughs specifically designed application distinctive to blend real‐world with material science. Firstly, we focus on main principles that facilitate release (e.g., CTCs EVs), leveraging their physicochemical properties. Then, applications are summarized, highlighting potential providing comprehensive information. Later, incorporation machine learning is also emphasized enhancing enabling deeper insights design next‐generation platforms specific biomarker isolation. Finally, future opportunities explored combining nanotechnologies artificial intelligence, thereby offering inconceivable possibilities improving care.
Язык: Английский
Процитировано
51
European Urology, Год журнала: 2024, Номер 86(4), С. 301 - 311
Опубликована: Май 29, 2024
Circulating tumor DNA (ctDNA) can be used for sensitive detection of minimal residual disease (MRD). However, the probability detecting ctDNA in settings low burden is limited by number mutations analyzed and plasma volume available. We a whole-genome sequencing (WGS) approach patients with urothelial carcinoma.
Язык: Английский
Процитировано
19
Nature Reviews Clinical Oncology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 20, 2025
Язык: Английский
Процитировано
3
EBioMedicine, Год журнала: 2025, Номер 114, С. 105636 - 105636
Опубликована: Март 23, 2025
Язык: Английский
Процитировано
3
Nature Reviews Clinical Oncology, Год журнала: 2024, Номер 22(1), С. 65 - 77
Опубликована: Ноя. 28, 2024
Язык: Английский
Процитировано
15
Clinical Chemistry, Год журнала: 2024, Номер 70(1), С. 220 - 233
Опубликована: Янв. 1, 2024
Abstract Background Liquid biopsy testing, especially molecular tumor profiling of circulating DNA (ctDNA) in cell-free plasma, has received increasing interest recent years as it serves a reliable alternative for the detection tumor-specific aberrations to guide treatment decision-making oncology. Many (commercially available) applications have been developed, however, broad divergences (pre)analytical work flows and lack universally applied guidelines impede routine clinical implementation. In this review, critical factors blood-based ctDNA liquid flow are evaluated. Content preanalytical phase, several aspects (e.g., blood collection tubes [BCTs], plasma processing, extraction method) affect quantity quality (ccfDNA) applicable subsequent analyses should meet certain standards be diagnostic flows. Analytical considerations, such analytical input choice assay, might vary based on application (i.e., screening, primary diagnosis, minimal residual disease [MRD], response monitoring, resistance identification). addition practical procedures, variant interpretation reporting results harmonized. Collaborative efforts (inter)national consortia societies essential establishment standard operating procedures (SOPs) attempts standardize plasma-based analysis flow. Summary Development regarding testing necessary pave way implementation diagnostics.
Язык: Английский
Процитировано
13
Cancer Letters, Год журнала: 2024, Номер unknown, С. 217350 - 217350
Опубликована: Ноя. 1, 2024
Pancreatic cancer remains one of the most challenging malignancies to treat due its late-stage diagnosis, aggressive progression, and high resistance existing therapies. This review examines latest advancements in early detection, therapeutic strategies, with a focus on emerging biomarkers, tumor microenvironment (TME) modulation, integration artificial intelligence (AI) data analysis. We highlight promising including microRNAs (miRNAs) circulating DNA (ctDNA), that offer enhanced sensitivity specificity for early-stage diagnosis when combined multi-omics panels. A detailed analysis TME reveals how components such as cancer-associated fibroblasts (CAFs), immune cells, extracellular matrix (ECM) contribute therapy by creating immunosuppressive barriers. also discuss interventions target these components, aiming improve drug delivery overcome evasion. Furthermore, AI-driven analyses are explored their potential interpret complex data, enabling personalized treatment strategies real-time monitoring response. conclude identifying key areas future research, clinical validation regulatory frameworks AI applications, equitable access innovative comprehensive approach underscores need integrated, outcomes pancreatic cancer.
Язык: Английский
Процитировано
11
Nature Reviews Urology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 15, 2025
Язык: Английский
Процитировано
1
eLife, Год журнала: 2023, Номер 12
Опубликована: Окт. 11, 2023
Despite their promise, circulating tumor DNA (ctDNA)-based assays for multi-cancer early detection face challenges in test performance, due mostly to the limited abundance of ctDNA and its inherent variability. To address these challenges, published date demanded a very high-depth sequencing, resulting an elevated price test. Herein, we developed multimodal assay called SPOT-MAS (screening presence by methylation size) simultaneously profile methylomics, fragmentomics, copy number, end motifs single workflow using targeted shallow genome-wide sequencing (~0.55×) cell-free DNA. We applied 738 non-metastatic patients with breast, colorectal, gastric, lung, liver cancer, 1550 healthy controls. then employed machine learning extract multiple cancer tissue-specific signatures detecting locating cancer. successfully detected five types sensitivity 72.4% at 97.0% specificity. The sensitivities early-stage cancers were 73.9% 62.3% stages I II, respectively, increasing 88.3% stage IIIA. For tumor-of-origin, our achieved accuracy 0.7. Our study demonstrates comparable performance other ctDNA-based while requiring significantly lower depth, making it economically feasible population-wide screening.
Язык: Английский
Процитировано
20
eLife, Год журнала: 2023, Номер 12
Опубликована: Июль 25, 2023
Despite their promise, circulating tumor DNA (ctDNA)-based assays for multi-cancer early detection face challenges in test performance, due mostly to the limited abundance of ctDNA and its inherent variability. To address these challenges, published date demanded a very high-depth sequencing, resulting an elevated price test. Herein, we developed multimodal assay called SPOT-MAS (screening presence by methylation size) simultaneously profile methylomics, fragmentomics, copy number, end motifs single workflow using targeted shallow genome-wide sequencing (~0.55×) cell-free DNA. We applied 738 non-metastatic patients with breast, colorectal, gastric, lung, liver cancer, 1550 healthy controls. then employed machine learning extract multiple cancer tissue-specific signatures detecting locating cancer. successfully detected five types sensitivity 72.4% at 97.0% specificity. The sensitivities early-stage cancers were 73.9% 62.3% stages I II, respectively, increasing 88.3% stage IIIA. For tumor-of-origin, our achieved accuracy 0.7. Our study demonstrates comparable performance other ctDNA-based while requiring significantly lower depth, making it economically feasible population-wide screening.
Язык: Английский
Процитировано
19